Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year.
The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients.
ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
On October 17th, Sharecast reported that news of progress in these trials would have a positive read-across for Angel, which has been supplying stem cells used in these trials.
CM
